Chee Man Cheong1, Annie W S Chow2, Stephen Fitter1, Duncan R Hewett3, Sally K Martin4, Sharon A Williams1, L Bik To5, Andrew C W Zannettino6, Kate Vandyke7. 1. Myeloma Research Laboratory, School of Medical Sciences, University of Adelaide, and South Australian Health and Medical Research Institute (SAHMRI), Adelaide 5000, SA, Australia. 2. Myeloma Research Laboratory, School of Medical Sciences, University of Adelaide, and South Australian Health and Medical Research Institute (SAHMRI), Adelaide 5000, SA, Australia; Department of Haematology, SA Pathology, Adelaide 5000, SA, Australia. 3. Myeloma Research Laboratory, School of Medical Sciences, University of Adelaide, and South Australian Health and Medical Research Institute (SAHMRI), Adelaide 5000, SA, Australia; School of Medicine, University of Adelaide, Adelaide 5005, SA, Australia. 4. Myeloma Research Laboratory, School of Medical Sciences, University of Adelaide, and South Australian Health and Medical Research Institute (SAHMRI), Adelaide 5000, SA, Australia; Department of Haematology, SA Pathology, Adelaide 5000, SA, Australia; School of Medicine, University of Adelaide, Adelaide 5005, SA, Australia. 5. Department of Haematology, SA Pathology, Adelaide 5000, SA, Australia. 6. Myeloma Research Laboratory, School of Medical Sciences, University of Adelaide, and South Australian Health and Medical Research Institute (SAHMRI), Adelaide 5000, SA, Australia; Department of Haematology, SA Pathology, Adelaide 5000, SA, Australia; School of Medicine, University of Adelaide, Adelaide 5005, SA, Australia; Centre for Cancer Biology and Hanson Institute, SA Pathology, Adelaide 5000, SA, Australia; Centre for Personalised Cancer Medicine, University of Adelaide, Adelaide 5000SA, Australia. 7. Myeloma Research Laboratory, School of Medical Sciences, University of Adelaide, and South Australian Health and Medical Research Institute (SAHMRI), Adelaide 5000, SA, Australia; Department of Haematology, SA Pathology, Adelaide 5000, SA, Australia; School of Medicine, University of Adelaide, Adelaide 5005, SA, Australia. Electronic address: kate.vandyke@health.sa.gov.au.
Abstract
BACKGROUND: Increased expression of the tetraspanin TSPAN7 has been observed in a number of cancers; however, it is unclear how TSPAN7 plays a role in cancer progression. METHODS: We investigated the expression of TSPAN7 in the haematological malignancy multiple myleoma (MM) and assessed the consequences of TSPAN7 expression in the adhesion, migration and growth of MM plasma cells (PC) in vitro and in bone marrow (BM) homing and tumour growth in vivo. Finally, we characterised the association of TSPAN7 with cell surface partner molecules in vitro. RESULTS: TSPAN7 was found to be highly expressed at the RNA and protein level in CD138(+) MM PC from approximately 50% of MM patients. TSPAN7 overexpression in the murine myeloma cell line 5TGM1 significantly reduced tumour burden in 5TGM1/KaLwRij mice 4 weeks after intravenous adminstration of 5TGM1 cells. While TSPAN7 overexpression did not affect cell proliferation in vitro, TSPAN7 increased 5TGM1 cell adhesion to BM stromal cells and transendothelial migration. In addition, TSPAN7 was found to associate with the molecular chaperone calnexin on the cell surface. CONCLUSION: These results suggest that elevated TSPAN7 may be associated with better outcomes for up to 50% of MM patients.
BACKGROUND: Increased expression of the tetraspanin TSPAN7 has been observed in a number of cancers; however, it is unclear how TSPAN7 plays a role in cancer progression. METHODS: We investigated the expression of TSPAN7 in the haematological malignancy multiple myleoma (MM) and assessed the consequences of TSPAN7 expression in the adhesion, migration and growth of MM plasma cells (PC) in vitro and in bone marrow (BM) homing and tumour growth in vivo. Finally, we characterised the association of TSPAN7 with cell surface partner molecules in vitro. RESULTS:TSPAN7 was found to be highly expressed at the RNA and protein level in CD138(+) MM PC from approximately 50% of MM patients. TSPAN7 overexpression in the murinemyeloma cell line 5TGM1 significantly reduced tumour burden in 5TGM1/KaLwRij mice 4 weeks after intravenous adminstration of 5TGM1 cells. While TSPAN7 overexpression did not affect cell proliferation in vitro, TSPAN7 increased 5TGM1 cell adhesion to BM stromal cells and transendothelial migration. In addition, TSPAN7 was found to associate with the molecular chaperone calnexin on the cell surface. CONCLUSION: These results suggest that elevated TSPAN7 may be associated with better outcomes for up to 50% of MM patients.
Authors: Chee Man Cheong; Krzysztof M Mrozik; Duncan R Hewett; Elyse Bell; Vasilios Panagopoulos; Jacqueline E Noll; Jonathan D Licht; Stan Gronthos; Andrew C W Zannettino; Kate Vandyke Journal: Cancer Lett Date: 2020-01-31 Impact factor: 8.679
Authors: Duncan R Hewett; Kate Vandyke; David M Lawrence; Natasha Friend; Jacqueline E Noll; Joel M Geoghegan; Peter I Croucher; Andrew C W Zannettino Journal: Neoplasia Date: 2017-11-05 Impact factor: 5.715
Authors: Craig T Wallington-Beddoe; Melissa K Bennett; Kate Vandyke; Lorena Davies; Julia R Zebol; Paul A B Moretti; Melissa R Pitman; Duncan R Hewett; Andrew C W Zannettino; Stuart M Pitson Journal: Oncotarget Date: 2017-07-04
Authors: Krzysztof M Mrozik; Chee M Cheong; Duncan R Hewett; Jacqueline E Noll; Khatora S Opperman; Alaknanda Adwal; Darryl L Russell; Orest W Blaschuk; Kate Vandyke; Andrew C W Zannettino Journal: FASEB Bioadv Date: 2020-06-15
Authors: Khatora S Opperman; Kate Vandyke; Kimberley C Clark; Elizabeth A Coulter; Duncan R Hewett; Krzysztof M Mrozik; Nisha Schwarz; Andreas Evdokiou; Peter I Croucher; Peter J Psaltis; Jacqueline E Noll; Andrew Cw Zannettino Journal: Neoplasia Date: 2019-06-24 Impact factor: 5.715
Authors: Bin Yang; Nicolas Sylvius; Jinli Luo; Cheng Yang; Zhanyun Da; Charlottelrm Crotty; Michael L Nicholson Journal: Front Immunol Date: 2021-07-01 Impact factor: 7.561
Authors: Jacqueline E Noll; Kate Vandyke; Duncan R Hewett; Krzysztof M Mrozik; Rachel J Bala; Sharon A Williams; Chung H Kok; Andrew Cw Zannettino Journal: J Hematol Oncol Date: 2015-10-06 Impact factor: 17.388